Sign in
4

Changes in Ownership

SAB Biotherapeutics, Inc. Filed Acc 0001493152-21-028917

Chief Financial Officer sold 278 shares at $7.90 ($2,196)

  • Chief Financial Officer acquired 2,768 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Beyer Russell P · Chief Financial Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2021-10-18 Grant or award : show line 1 in the form +2,475 $10.10 $24,998 2,475 D
2021-09-28 Grant or award : show line 2 in the form +149 $10.08 $1,502 149 I
2021-10-25 Grant or award : show line 3 in the form +129 $7.78 $1,004 278 I
2021-10-26 Sale : show line 4 in the form −278 $7.90 $2,196 0 I
2021-09-28 Grant or award : show line 5 in the form +5 $10.07 $50 5 I
2021-09-29 Grant or award : show line 6 in the form +10 $10.08 $101 15 I
Open-market sales · 278 sh · avg $7.90 · $2,196
Loading xslF345X03/ownership.xml…